Skip to Content
Interactive Textbook on Clinical Symptom Research Logo


Home button

Trial Design: Pain Sections
Author Bio
Introduction
Placebo Effects
Single Dose Trials
Repeated Dose Trials
Explanatory Versus Pragmatic
Currently selected section: Dose-Response
Parallel Group Versus Crossover
Conclusion
 

 

Chapter 1: Clinical Trials of Pain Treatment: Dose-Response; Relative Potency; Combinations

 
           

Dose-Response Studies (Continued)

Because most responses to drugs vary with the logarithm of the dose, investigators commonly choose doses in exponential ratios--e.g. 10 mg, 20 mg, and 40 mg. For reasons discussed in Section 3 of this chapter, one may wish to include a placebo and standard analgesic control.

Rather than proceeding in the two above steps, one may wish to get initial efficacy and dose-response information from the same patient group. One option is to use a prospective dose-response study as the initial study. Because some patients will be getting low, ineffective doses, this may be somewhat less efficient than a "sledgehammer study" in establishing the principle of drug efficacy. Some of this power may be salvaged by carrying out a dose-response regression, where a statistically significant regression coefficient is generally viewed as evidence of efficacy. Another possibility is to use a two-stage crossover trial in which patients are initially titrated to their maximal tolerated dose (MTD) or placebo, and responders are then randomly assigned to various proportions (say 0, 25, 50, and 100%) of the MTD.

 

Page 34 of 52
      Previous Page